Tillement J P, Lhoste F, Giudicelli J F
Clin Pharmacokinet. 1978 Mar-Apr;3(2):144-54. doi: 10.2165/00003088-197803020-00004.
In a number of pathological states a decrease in the plasma protein binding of drugs is observed. This may be due to many factors related either to the protein, or the ligand (drug), or to the binding conditions. The most important of these disease states quantitatively are probably hypoalbuminaemia, conditions resulting in modification of the albumin compartment volume and the presence on albumin binding sites of pathological inhibitors of drug binding. A decrease in the extent of drug plasma protein binding does not necessarily lead to enhanced drug effects and therefore raises two important therapeutic questions. Firstly, does reduced protein binding have a clinically significant influence on the pharmacological effects of the drug? Secondly, if it does, is it preferable to modify the dosage regimen of the drug or to correct the plasma protein concentration prior to the administration of the drug? At present, only tentative answers can be given.
在一些病理状态下,会观察到药物的血浆蛋白结合率降低。这可能是由于许多与蛋白质、配体(药物)或结合条件相关的因素。从数量上来说,这些疾病状态中最重要的可能是低白蛋白血症、导致白蛋白区室容积改变的情况以及药物结合的病理性抑制剂存在于白蛋白结合位点上。药物血浆蛋白结合程度的降低不一定会导致药物作用增强,因此引发了两个重要的治疗问题。首先,蛋白结合率降低对药物的药理作用是否有临床显著影响?其次,如果有影响,在给药前是调整药物的给药方案还是纠正血浆蛋白浓度更可取?目前,只能给出初步的答案。